万拉法新与氯丙咪嗪治疗精神分裂症后抑郁对照研究

目的 验证万拉法新治疗精神分裂症后抑郁的疗效及安全性。方法 对65例精神分裂症后抑郁患者随机入组,分别以万拉法新与氯丙咪嗪治疗6周。采用汉密尔顿抑郁量表(HAMD)、简明精神病量表(BPRS)、阴性症状量表(SANS)评定临床疗效,采用副反应量表(TESS)评定副反应。结果 万拉法新组与氯丙咪嗪组治疗前后HAMD、BRPS、SANS评分及减分率比较均无显著性差异(P>0.05)。万拉法新组的副反应较氯丙咪嗪组少而轻,但各有1例精神病症状恶化。结论 万拉法新治疗精神分裂症后抑郁的疗效确切,但极个别病例精神病症状恶化。

A clinical control study of venlafaxine and clomipramine in the treatment of post-schizophrenic depression

Objective To verify the clinical efficacy and the side effects of venlafaxine in the treatment of post-schizophrenic depression. Methods 65 patients meeting CCMD-2-R criteria for post-schizophrenic depression were randomly assigned to venlafaxine group (n=33) and clomipramine group (n = 32) for six weeks. Effects and side reactions were evaluated with Hamilton Rating Scale for Depression ( HAMD) , Brief Psychiatric Rating Scale (BPRS),the Scale for Assessment of Negative Symptoms (SANS) and Treatment Symptoms Scale (TESS) before and after 2,4,6 - week treatment respectively. Results The scores and the reductive scores of HAMD..BPRS and SANS had no significant difference betweeft the two groups. Compared with clomipramine, venlafaxine had fewer side effects,but there was one relapse schizophrenic patient in every group. Conclusion Venlafaxine is an effective antidepressant in the treatment of post-schizophrenic depression,but it may make schizophrenia relapse.